Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Marginal Zone B-Cell Lymphoma

New E-Learning module by Prof Markus Raderer is now available. Watch the presentation and take the CME test today!

E-learning video block

This content is for ESMO members only.



Download slides

Learning objectives

  1. To understand that marginal zone B-cell lymphoma comprises three distinct entities and although they are related to their histogenetic origins, each displays its own clinical and biological characteristics that are reflected in the diagnosis, therapy and outcome
  2. To understand how the rarity and heterogeneity of marginal zone B-cell lymphoma impact the patient management
  3. To provide an update on the main features, clinical presentation, diagnosis, and treatment approaches for marginal zone B-cell lymphoma subtypes


Marginal zone lymphoma (MZL) is a group of indolent non-Hodgkin, B-cell lymphomas. In this module, the author tackles basic considerations with a distinction between nodal and extranodal lymphomas and describes MZL related entities, clinical presentation, diagnosis, genetics, treatment strategies, and outcomes.

Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) comprises 7-8% of NHL cases, splenic 0.6-2%, and nodal MZL 1%. The author describes the characteristics of extranodal marginal zone B-cell lymphoma of MALT, clinical presentation of nodal MZL versus MALT, and, by describing the genetics of nodal and splenic MZL, elaborates treatment approaches for splenic MZL.

The next  chapter covers the distribution of MALT lymphomas, the distinct mutation profiles in MALT lymphoma of various sites, clinical distribution, clinical outcomes according to MALT-IPI risk groups, bone marrow involvement, and risk of transformation.

Furthermore, the author elaborates infections and MZL, Helicobacter pylori eradication therapy and its efficacy, treatment recommendations, assessment of response, MZL and autoimmune diseases, Helicobacter pylori-negative gastric MALT lymphoma, involvement of non-Helicobacter pylori Helicobacter infections, treatment recommendations beyond antibiotics, and long-term outcomes.

Moreover, the module gives an overview on radiotherapy for follicular and MZL, systemic treatment, radioimmunotherapy monoclonal antibodies, anti-CD20 treatment in MALT lymphoma and selected chemotherapy studies: upfront chemotherapy-based treatment of MALT lymphoma, chemotherapy-free approaches, and time to best response, delayed efficacy, study results with Bruton’s tyrosine kinase inhibitor, as well as results of chemotherapy versus immunotherapy.

The final part of the module provides a summary of the treatment recommendations for MALT lymphoma. Helicobacter pylori eradication is standard for gastric MALT lymphoma. Ocular adnexal MALT lymphoma may also be treated with antibiotics upfront. Both radiotherapy and systemic therapy may be applied in localised disease. The optimal systemic standard remains to be defined: chemotherapy (plus antibody) for quick remissions, and immunotherapy in patients with indolent disease.

Declaration of interest

Markus Raderer has reported:
Financial interests:
Advisory Board, Personal: Gilead , Roche, Eli Lilly, Johnson & Johnson.
Invited Speaker, Personal: Ipsen .

Last update: 11 Oct 2022

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.